指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

多国癌症支持治疗协会(MASCC)标准:急诊科中性粒细胞减少症管理的评价与建议

The Multinational Association for Supportive Care in cancer criteria. An Evaluation and recommendations for the management of neutropenia in the emergency department.
指南 / 共识 · Int Emerg Nurs · 2024-11-19
一句话结论回顾性队列显示MASCC评分对急诊中性粒细胞减少症真实临床紧急度的识别不佳,但原始风险分层与分诊至再评估时间、就诊时间、决定住院时间、待床至处置时间及住院时长显著相关,并与院内死亡转归显著相关(p<0.05)。

本研究采用回顾性队列设计,评价MASCC标准在急诊中性粒细胞减少症患者中的可重复性、准确性、可行性及其对急诊临床决策、治疗和健康结局的影响。MASCC评分识别高紧急度患者的能力较好(高紧急度患者中70%被识别为高风险),但识别低紧急度患者的能力较差(低紧急度患者中仅30%被识别为低风险)。将MASCC评分作为连续变量分析价值有限且效度较低;似然比远未达良好水平,更适用于排除高紧急度;MASCC 17~20分段的观察似然比等于1,对量表区分度无信息。多因素线性回归显示MASCC原始分类(高/低风险)和所研究的新分类(MASCC评分多个区间)均与再评估时间、接诊时间、决定住院时间、待床至处置时间及住院时长显著相关,但两者均不能预测收治地点;两者均与医院转归(死亡率)显著相关(p<0.05)。结论认为,尽管MASCC评分决定中性粒细胞减少症的治疗路径,但敏感度和特异度分析显示该量表在识别真实临床紧急度方面表现不佳。

要点

  • MASCC评分对高紧急度患者的识别率为70%(高紧急度患者中被判为高风险),对低紧急度患者的识别率仅30%(低紧急度患者中被判为低风险)。
  • MASCC评分作为连续变量分析价值有限且效度较低;似然比远未达良好,更适用于排除高紧急度。
  • MASCC 17~20分段的观察似然比等于1,对量表区分度无信息。
  • MASCC原始分类(高/低风险)与新分类(多个评分区间)均与再评估时间、接诊时间、决定住院时间、待床至处置时间及住院时长显著相关,但均不能预测收治地点。
  • MASCC原始分类与新分类均与医院转归(死亡率)显著相关(p<0.05)。

适用人群与场景

  • 急诊科就诊的中性粒细胞减少症患者(回顾性队列)

诊断标准与关键阈值

  • MASCC评分高风险与低风险分类(原始分类);MASCC评分多个区间的新分类。
  • MASCC评分17~20分段:观察似然比等于1,对量表区分度无信息。

处置流程与药物剂量

  • MASCC评分决定中性粒细胞减少症的治疗路径。

研究设计与关键结果

  • 研究类型:回顾性队列设计,评价MASCC标准的可重复性、准确性、可行性及其对急诊临床决策、治疗和健康结局的影响。
  • MASCC评分正确识别高紧急度:高紧急度患者中70%被识别为高风险;正确识别低紧急度:低紧急度患者中仅30%被识别为低风险。
  • MASCC评分作为连续变量分析价值有限且效度较低;似然比远未达良好,更适用于排除高紧急度;MASCC 17~20分段的观察似然比等于1,对量表区分度无信息。
  • 多因素线性回归:MASCC原始分类(高 vs 低风险)与新分类(MASCC评分多个区间)均与再评估时间、接诊时间、决定住院时间、待床至处置时间及住院时长显著相关;但两者均不能预测收治地点;两者均与医院转归(死亡率)显著相关(p<0.05)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • MASCC评分决定中性粒细胞减少症的治疗路径,但敏感度和特异度分析显示该量表在识别真实临床紧急度方面表现不佳(作者结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: We aimed to evaluate the reproducibility, accuracy, feasibility, and effect of the Multinational Association for Supportive Care in Cancer (MASCC) criteria on emergency clinical decisions, treatment, and health outcomes.

METHODS: A retrospective cohort design was used.

RESULTS: The MASCC score was better at correctly detecting the high urgency (70 % of patients with a high urgency were identified as high risk) than the low urgency (only 30 % of patients with a low urgency were identified as low risk). The examination of the MASCC score as a continuous variable could have been more valuable and indicated inferior validity. The likelihood ratios were far from good, which is better for ruling out the high urgency. The observed likelihood ratio of the MASCC range 17 to 20 provided no information for the goodness of the scale (equal to one). The results from multiple linear regression analyses identified that the MASCC original categorization (high vs. low risk) and the investigated new one (multiple ranges of MASCC score) were significantly associated with time to reassessment, time to be seen, time to decide on admission, boarding time until disposition, and length of stay. However, the original categorization nor the new one was predictive of the admission site. Still, both were significantly associated with hospital disposition (mortality) (p < 0.05).

CONCLUSION: Even though the MASCC score determines the neutropenia treatment pathway, the sensitivity and specificity analysis identified that the scale did not perform well in detecting real clinical urgency.

来源:Int Emerg Nurs,查看原文。版权归原作者所有。

参考来源

  1. Alsharawneh A. The Multinational Association for Supportive Care in cancer criteria. An Evaluation and recommendations for the management of neutropenia in the emergency department. Int Emerg Nurs. 2024. PMID: 39566439. doi:10.1016/j.ienj.2024.101542

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。